REGIONAL VACCINATION PROGRAM FOR THE PREVENTION OF HPV-ASSOCIATED DISEASES IN THE KHMAO-YUGRA

Cover Page


Cite item

Full Text

Abstract

Abstract. Unlike other malignancies, only for cervical cancer a viral etiology in all cases has been proved. This evidencing a unique opportunity to prevent this type of cancer by vaccination against HPV. Implementation of preventive vaccination against HPV infection in routine clinical practice will reduce cancer risk in population and decrease the probability of early cervical cancer and other HPV-associated diseases. In 2014 Ugra actively started school vaccination program for teenage of 12 years-girls.

About the authors

L. D. Belotsercovtseva

Surgut State University, Surgut; Surgut Clinical Perinatal Center, Surgut

Email: calm332@mail.ru
PhD, MD (Medicine), Professor, Head of the Department of Obstetrics, Gynecology and Perinatology, Surgut State University, Head of Surgut Clinical Perinatal Center Россия

Yu. I. Mayer

Surgut State University, Surgut

Author for correspondence.
Email: calm332@mail.ru

PhD (Medicine), Associate Professor, Department of Obstetrics, Gynecology and Perinatology, Surgut State University, Chief Specialist in Pediatric Gynecology of Department of Health KHMAO-Yugra

628400, Russian Federation, KHMAO-Ugra, Surgut, Gubkina str., 1

 

 

Россия

S. V. Leskova

Clinical Municipal Policlinic No. 1, Surgut

Email: calm332@mail.ru
PhD (Medicine), Head of Female Consultation Россия

References

  1. Бычкова О.С., Коколина В.Ф. Современные представления о папилломавирусной инфекции у детей и подростков // Репродуктивное здоровье детей и подростков. — 2010. — № 1. — С. 43–51. Bychkova O.S., Kokolina V.F. Sovremennye predstavlenija o papillomavirusnoj infekcii u detej i podrostkov [Modern conceptions of human papillomavirus infection in children and adolescents]. Reproduktivnoe zdorov’e detej i podrostkov — Reproductive Health of Children and Adolescents, 2010, no. 1, pp. 43–51.
  2. Галицкая М.Г., Намазова-Баранова Л.С., Ткаченко Н.Е., Гайворонская А.Г. Вакцинация против папилломавирусной инфекции: безопасное решение глобальной проблемы // Педиатрич. фармакология. — 2011. — Т. 8, № 4. — С. 82–86. Galickaja M.G., Namazova-Baranova L.S., Tkachenko N.E., Gajvoronskaja A.G. Vakcinacija protiv papillomavirusnoj infekcii: bezopasnoe reshenie global’noj problemy [Vaccination against human papillomavirus infection: a safe solution to the global problem]. Pediatricheskaja farmakologija— Pediatric Pharmacology, 2011, vol. 8, no. 4, pp. 82–86.
  3. Гомберг М.А., Соловьев А.М., Чернова Н.И., Исаева С.Г. Генитальные бородавки: эффективные методы лечения // Медицинский вестник. — 2010. — № 5–6. — С. 10–12. Gomberg M.A., Solov’ev A.M., Chernova N.I., Isaeva S.G. Genital’nye borodavki: jeffektivnye metody lechenija [Genital warts: Effective Treatments]. Medicinskij vestnik — Medical Bulletin, 2010, no. 5–6, pp. 10–12.
  4. Каприн А.Д., Старинский В.В., Петрова В.Г. Состояние онкологической помощи населению России в 2012 г. — М.: ФГБУ «МНИОИ им. Герцена», 2013. — 230 с. Kaprin A.D., Starinskij V.V., Petrova V.G. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2012 g. [Status of cancer care in Russia in 2012]. Moscow: MNIOI named after Gercen, 2013. 230 p.
  5. Концепция и стратегия глобальной иммунизации. Доклад секретариата. ВОЗ. 25 ноября 2010 года. http://apps.who.int/gb/ebwha/pdf_files/EB128/B128_9-ru.pdf. Koncepcija i strategija global’noj immunizacii. Doklad sekretariata. VOZ. 25 nojabrja 2010 goda [Vision and strategy for global immunization. Report by the Secretariat. WHO. November 25, 2010]. Available at http://apps.who.int/gb/ebwha/pdf _files/EB128/B128_9-ru.pdf.
  6. Кумыкова З.Х., Уварова Е.В. Распространенность и естественное течение ВПЧ-инфекции и ВПЧ-ассоциированных поражений шейки матки у девочек-подростков // Репродуктивное здоровье детей и подростков. — 2009. — № 5 — С. 35–46. Kumykova Z.H., Uvarova E.V. Rasprostranennost’ i estestvennoe techenie VPCh-infekcii i VPCh-associirovannyh porazhenij shejki matki u devochek-podrostkov [Prevalence and natural course of HPV infection and HPV -associated cervical lesions in adolescent girls]. Reproduktivnoe zdorov’e detej i podrostkov — Reproductive Health of Children and Adolescents, 2009, no. 5, pp. 35–46.
  7. Минкина Г.Н. Квадривалентная вакцина Гардасил в профилактике рака шейки матки и генитальных кондилом // Здоровье будущих поколений: новые технологии и новые возможности медицины: материалы науч.-практ. конф. — М.: 2007. — С. 12–17. Minkina G.N. Kvadrivalentnaja vakcina Gardasil v profilaktike raka shejki matki i genital’nyh kondilom [Quadrivalent vaccine Gardasil in prevention of cervical cancer and genital warts]. Zdorov’e budushhih pokolenij: novye tehnologii i novye vozmozhnosti mediciny: materialy nauch.-prakt. konf. [Health of future generations, new technologies and new opportunities medicine: proceedings of scientific-practical conference]. Moscow, 2007, pp. 12–17.
  8. Рудакова А.В. В ожидании расширения календаря прививок // 17 Съезд педиатров России, 13–17 февраля 2013. Rudakova A.V. V ozhidanii rasshirenija kalendarja privivok [In anticipation of the immunization schedule expanding] 17 S’ezd pediatrov Rossii, 13–17 fevralja 2013 [17 Congress of pediatricians of Russia, 13–17 February 2013].
  9. Чиссов В.И. Злокачественные новообразования в России в 2011. Заболеваемость и смертность. — М., 2013. Chissov V.I. Zlokachestvennye novoobrazovanija v Rossii v 2011. Zabolevaemost’ i smertnost’ [Malignancies in Russia in 2011. Morbidity and mortality]. Moscow, 2013.
  10. Ali H., Guy R., Wand H., Read T., Regan D., Grulich A., Fairley Ch., Donovan B. Decline in in-patient treatments of genital warts among young australians following the national HPV vaccination program. BMC Infect. Dis., 2013, no. 13, pp. 140.
  11. Australia Therapeutic Goods Administration/Australia Government. Available at: http://agencysearch.australia.gov.au/s/search.html?query=gardasil&collection=agencies&profile=tga.
  12. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K.K., Kjaer S.K. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex. Transm. Dis., 2013, vol. 40, pp. 130–135.
  13. Bresse X., Cassel T., Adam M. Universal vaccination against 6/11/16/18 HPV-related diseases in Sweden: towards HPV disease control. EUROGIN 2013, European Research Organization on Genital Infection and Neoplasia 2013, International Multidisciplinary Congress, Florence, Italy. Abstract P 3–3.
  14. Bresse X., Goergen C., Prager B., Joura E. Universal vaccination with the quadrivalent HPV vaccine in Austria: Impact on virus circulation, public health and cost-effectiveness analysis. Expert Rev. Pharmacoecon. Outcomes Res. 2014, Early Online, January, 22, 2014.
  15. Brotherton J., Fridman M., May C., Chappell G., Saville M., Gertig D. Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study. Lancet, 2011, no. 377:2085, p. 92.
  16. Burchell A., Winer R., de Sanjos S., Franco E. Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 24S3, 2006, S3/52-S3/61.
  17. Canada Communicable Diseases Report: Update On Human Papillomavirus (HPV) Vaccines. An Advisory Committee Statement (ACS) (NACI), January 2012, vol. 38. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1.
  18. Clinical review of biologics license application for Human Papillomavirus 6, 11, 16, 18 L1 virus like particle vaccine. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111287.pdf.
  19. Concept paper for a guideline on the conduct of pharmacovigilance for vaccines. European Medicines Agency, 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline.
  20. Dana A., Buchanan K.M., Goss M.A., Seminack M.M., Shields K.E., Korn S. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol., 2009, vol. 114 (6), pp. 1170–1178.
  21. Donovan B., Franklin N., Guy R., Grulich A., Regan D., Ali H., Wand H., Fairley Ch. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect. Dis., 2011, no. 11, pp. 39–44.
  22. Dunne E.F., Friedman A., Datta S.D, Markowitz L.E., Workowski K.A. Updates on Human Papillomavirus and Genital Warts and Counseling Messages From the 2010. Sex. Transm. Dis. Treat., Guidelines, Clin. Infect. Dis., 2011, vol. 53 (suppl. 3), pp. 143–152.
  23. FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 2010, pp. 340–349.
  24. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez J., Harper D.M., Leodolter S., Tang G., Ferris D.J., Steben M., Bryan J., Taddeo F.J., Railkar R., Esser M.T., Sings H.L., Nelson M, Boslego J., Sattler C., Barr E., Koutsky L.A. Quadrivalent vaccine against Human papillomavirus to prevent anogenital diseases. N. Engl.Med., no. 356, pp. 1154–1156.
  25. GLOBOCAN. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary. Accessed on 09/09/2012. Available at: www.who.int/hpvcentre.
  26. Goss M.A., Lievano F., Seminack M., Buchanan K., Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 5 year pregnancy registry data. Human Papillomavirus, Cervical Other Human Diseases, EUROGIN 2012, Abstr. SS 8–3. July 8–11, 2012, p. 123.
  27. Grulich A.E. Quadrivalent HPV vaccination and genital warts in Australia, 2004–2010. O-04.01. Abstractbook IPV 2011.
  28. Harris T., Williams D.M., Fediurek J., Scott T., Deeks S.L. Adverse events following immunization in Ontario’s female school-based HPV program. Vaccine, 2014, vol. 32, no. 9, pp. 1061.
  29. Human Papillomavirus and Related Diseases Report/World/ Version posted on www.hpvcenter.net in March 17, 2014.
  30. Introduction of HPV vaccines in European Union countries-un update. 2012. Available at: http://www.ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.
  31. Kothari S., Nwankwo C., Pillsbury M. The health and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Columbia: A Transmis. Dyn. Model-Based Evaluation. Value Health, A713 Abstr. PIN11 2013, Nov 2–6 2013, vol. 16, no. 7.
  32. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet, 2006, pp. 489–498.
  33. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., Unger E.R. Reduction in Human Papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States. National Health and Nutrition Examination Surveys, 2003–2010. J. Infect. Dis. Advance Access published, June 19, 2013.
  34. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. HPV in the etiology of human cancer. Vaccine 24S3, 2006, S3/1–S3/10.
  35. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., Lewis N., Deosaransingh K., Sy L., Ackerson B., Cheetham T.C., Liaw K-L., Takhar H., Jacobsen S.J. Safety of quadrivalent Human papillomavirus vaccine administered routinely to females. American medical association, 2012. Available at: www.archpediatrics.com.
  36. Prymula R., Anca I., André F., Bakir M. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur. J. Pediatr., 2009, vol. 168, no. 9, pp. 1031–1035.
  37. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programmу. Sex. Transm. Infect., 2011.
  38. Recommendations on the use of quadrivalent Human papillomavirus vaccine in males. Advisory Committee on Immunization Practices (ACIP), 2011. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm.
  39. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., Izurieta H.S., Ball R., Miller N., Braun M.M., Markowitz L.E., Iskander J. Post licensure safety surveillance for quadrivalenthuman papillomavirus recombinant vaccine. JAMA, 2009, no. 7, pp. 750–757.
  40. Stan L., Block M. Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16 and 18) L1 Virus-Like Particle Vaccine. Pediatr. Infect. Dis. J., 2010, vol. 29, no 2.
  41. Garland S.M., Ault K.A., Gall S.A., Paavonen J., Sings H.L., Ciprero K.L., Saah A., Marino D., Ryan D., Radley D., Zhou H., Haupt R.M., Garner E.I. Pregnancy and infant outcomes in the clinical trials of a Human Papillomavirus Type 6/11/16/18 Vaccine. A combined analysis of five randomized controlled trials. Obst. Gynecol., 2009, vol. 6, pp. 1179–1188.
  42. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., Bateson D., McNamee K., Garefalakis M. and Garland S.M. Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis., 2012, vol. 206 (11), pp. 1645–1651.
  43. The WHO Position Paperon Vaccines against Human Papillomavirus, 2009. Available at: http://www.who.int/immunization/documents/HPV_position_paper_summary.pdf?ua=1.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Belotsercovtseva L.D., Mayer Y.I., Leskova S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies